Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?

Bryan C Hambley; Ciprian Tomuleasa; Gabriel Ghiaur

doi:10.3389/fmed.2021.722614

Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?

Front Med (Lausanne). 2021 Aug 17:8:722614. doi: 10.3389/fmed.2021.722614. eCollection 2021.

Authors

Bryan C Hambley¹, Ciprian Tomuleasa^{2

3

4}, Gabriel Ghiaur^{4

5}

Affiliations

¹ Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.
² Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
³ Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.
⁴ Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
⁵ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Abstract

Acute promyelocytic leukemia (APL) is characterized by frequent complications due to a distinct coagulopathy. While advances in treatments have improved long-term survival, hemorrhagic and thrombotic complications remain the most common causes of death and morbidity. Improved understanding of the mechanisms of the coagulopathy associated with APL may lead to therapeutic interventions to mitigate the risk of hemorrhage and thrombosis.

Keywords: APL; ATRA; delayed bleeding; hemorrhage; hyperfibrinolysis; thrombosis.

Publication types

Review